Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to -$1.4 million.

  • KalVista Pharmaceuticals' Change in Account Payables fell 12282.72% to -$1.4 million in Q2 2025 from the same period last year, while for Apr 2025 it was $348000.0, marking a year-over-year decrease of 9194.44%. This contributed to the annual value of -$5.0 million for FY2025, which is 21506.94% down from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Change in Account Payables is -$1.4 million, which was down 12282.72% from -$5.9 million recorded in Q4 2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Change in Account Payables peaked at $6.1 million during Q2 2024, and registered a low of -$5.9 million during Q4 2024.
  • Over the past 3 years, KalVista Pharmaceuticals' median Change in Account Payables value was $55000.0 (recorded in 2023), while the average stood at -$204285.7.
  • Within the past 5 years, the most significant YoY rise in KalVista Pharmaceuticals' Change in Account Payables was 129074.07% (2024), while the steepest drop was 1075454.55% (2024).
  • Over the past 3 years, KalVista Pharmaceuticals' Change in Account Payables (Quarter) stood at $55000.0 in 2023, then plummeted by 10754.55% to -$5.9 million in 2024, then surged by 76.25% to -$1.4 million in 2025.
  • Its Change in Account Payables stands at -$1.4 million for Q2 2025, versus -$5.9 million for Q4 2024 and $1.5 million for Q3 2024.